BioCentury
ARTICLE | Financial News

Orphan play Lumos raises $34M

April 7, 2016 1:00 AM UTC

Lumos Pharma Inc. (Austin, Texas) raised $34 million in a series B round led by new investor Deerfield Management. New investors Clarus Ventures and Roche Venture Fund also participated, as did existing investors New Enterprise Associates, Sante Ventures and UCB Group (Euronext:UCB).

Lumos' LUM-001 is a small molecule creatine mimetic that is in preclinical development to treat creatine transporter deficiency (CTD), for which it has FDA Orphan Drug designation. Patients with the disease can synthesize creatine but cannot actively transport it across the blood-brain barrier. ...